Results 111 to 120 of about 724,283 (165)

Biosimilar CT-P13 comparable to infliximab in active RA [PDF]

Nature Reviews Rheumatology, 2013
openaire   +1 more source

Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. [PDF]

Drugs Real World Outcomes, 2022
Krstic M, Devaud JC, Marti J, Sadeghipour F.   +3 more
europepmc   +1 more source

Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease. [PDF]

Dig Dis Sci
Fathallah N, Draullette M, Kirchgesner J, Paul S, Roblin X, Bourrier A, Haouari MA, Chambenois E, Morisset S, Seksik P, de Parades V.   +10 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]

Adv Ther
Marotte H, Cantagrel A, Coury F, Schaeverbeke T, Assing M, Kessouri M, Brault Y, Fautrel B.   +7 more
europepmc   +1 more source

Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease. [PDF]

Intest Res
Nomaru R, Takeda T, Takahashi A, Mikumo H, Yasukawa S, Koga A, Kanemitsu T, Ono Y, Takatsu N, Miyaoka M, Hisabe T, Arima H, Imakiire S, Yamauchi E, Ashizuka S, Hirai F.   +15 more
europepmc   +1 more source

Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. [PDF]

Eur J Hosp Pharm, 2022
Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ.   +5 more
europepmc   +1 more source

Core-CT Project news

, 2001
Began with Sept.

core  

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. [PDF]

Inflamm Bowel Dis
Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, Kim SH, Bae YJ, Lee SH, Lee SG, Lee JH, Kim JM, Park GH, Lee J, Lee JH, Kim CY, Sands BE.   +16 more
europepmc   +1 more source

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]

J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB.   +32 more
europepmc   +1 more source

Remsima® – the first biosimilar infliximab CT-P13

Gastroenterologie a hepatologie, 2017
openaire   +1 more source